- Conditions
- HIV Infections, Leukoencephalopathy, Progressive Multifocal
- Interventions
- Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1997
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 68
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status, AMS
- Interventions
- Lactulose, Polyethylene Glycol 3350
- Drug
- Lead sponsor
- New York Presbyterian Brooklyn Methodist Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Toxoplasmosis, Cerebral, HIV Infections
- Interventions
- Pyrimethamine, Leucovorin calcium, Clindamycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1992
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
- Conditions
- Encephalitis, Meningitis
- Interventions
- mNGS for pathogen detection
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 1 Minute to 110 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 7
- States / cities
- Davis, California • Los Angeles, California • San Francisco, California + 3 more
- Conditions
- Equine Encephalitis
- Interventions
- MVA-BN-WEV Dose 1, MVA-BN-WEV Dose 2, MVA-BN-WEV Dose 3
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- West Nile Fever
- Interventions
- VRC-WNVDNA020-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections, Leukoencephalopathy, Progressive Multifocal
- Interventions
- Topotecan
- Drug
- Lead sponsor
- SmithKline Beecham
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
- Conditions
- Japanese Encephalitis
- Interventions
- ChimeriVax™-JE vaccine, JE-VAX® vaccine
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 48 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Encephalitis, Encephalitis, Viral, Infectious Encephalitis, Virus Diseases, Encephalomyelitis, Venezuelan Equine, Brain Diseases, Central Nervous System Diseases, Central Nervous System Viral Diseases, Alphavirus Infections, Togaviridae Infections, RNA Virus Infections, Central Nervous System Infections, Encephalomyelitis, Physiological Effects of Drugs, Vaccines, Encephalomyelitis, Equine, Nervous System Diseases
- Interventions
- Vaccinations on Day 0, Day 28, and Day 140
- Biological
- Lead sponsor
- SRI International
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Plymouth, Michigan
- Conditions
- Healthy, West Nile Fever, Healthy Volunteer, HV
- Interventions
- VRC-WNVDNA017-00-VP
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Brincidofovir
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Infectious Metabolic Encephalopathy, Ischemic Stroke, Seizure, Viral Encephalitis, Small and Large Vessel
- Interventions
- keypresses
- Behavioral
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Meningoencephalitis, Other Syndromes Requiring Lumbar Puncture in Emergency Department
- Interventions
- no intervention
- Other
- Lead sponsor
- Olive View-UCLA Education & Research Institute
- Other
- Eligibility
- 3 Months and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Sylmar, California
- Conditions
- Tick-Borne Encephalitis
- Interventions
- LGT(TP21)/DEN4, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Toxoplasmosis, Cerebral, HIV Infections
- Interventions
- Azithromycin, Pyrimethamine, Leucovorin calcium
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Miami, Florida • Worcester, Massachusetts + 5 more
- Conditions
- HSV Encephalitis
- Interventions
- To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus, NSI Protein, Flavivirus
- Interventions
- FSME-IMMUN 0.5ml Baxter
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Hamilton, Montana
- Conditions
- Subarachnoid Hemorrhage, Intracerebral Hemorrhage, Ventriculitis, Cerebral, Hydrocephalus
- Interventions
- Long term (continuous) prophylactic antibiotics, 24 hours antibiotics
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- West Nile Fever
- Interventions
- ChimeriVax-WN02 vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 479 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 15
- States / cities
- Anaheim, California • Colorado Springs, Colorado • South Miami, Florida + 12 more
- Conditions
- Acquired Immunodeficiency Syndrome, BK Virus Infection, Human Immunodeficiency Virus, JC Virus Infection, Malignant Neoplasm, Merkel Cell Carcinoma, Merkel Cell Polyomavirus Infection, Viral Encephalitis
- Interventions
- Allogeneic BK-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- West Nile Fever
- Interventions
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2009
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- Lupus Research Alliance
- Other
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 3,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
- Interventions
- 89 Zr-Df-crefmirlimab
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland